Greig NH - Search Results

1

An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK. Greig NH, et al. Curr Alzheimer Res. 2005 Jul;2(3):281-90. doi: 10.2174/1567205054367829. Curr Alzheimer Res. 2005. PMID: 15974893 Review.

2

The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.

Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, Ingram DK. Iijima S, et al. Among authors: greig nh. Neurosci Lett. 1992 Sep 14;144(1-2):79-83. doi: 10.1016/0304-3940(92)90720-r. Neurosci Lett. 1992. PMID: 1436716

3

Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.

Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, Soncrant TT. Asthana S, et al. Among authors: greig nh. Clin Pharmacol Ther. 1995 Sep;58(3):299-309. doi: 10.1016/0009-9236(95)90246-5. Clin Pharmacol Ther. 1995. PMID: 7554703 Clinical Trial.

4

Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase.

Ikari H, Spangler EL, Greig NH, Pei XF, Brossi A, Speer D, Patel N, Ingram DK. Ikari H, et al. Among authors: greig nh. Neuroreport. 1995 Feb 15;6(3):481-4. doi: 10.1097/00001756-199502000-00019. Neuroreport. 1995. PMID: 7766848

5

Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, Ingram DK. Iijima S, et al. Among authors: greig nh. Psychopharmacology (Berl). 1993;112(4):415-20. doi: 10.1007/BF02244888. Psychopharmacology (Berl). 1993. PMID: 7871051

6

Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.

Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A. Greig NH, et al. Med Res Rev. 1995 Jan;15(1):3-31. doi: 10.1002/med.2610150103. Med Res Rev. 1995. PMID: 7898167 Review. No abstract available.

7

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.

Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT. Asthana S, et al. Among authors: greig nh. Alzheimer Dis Assoc Disord. 1995 Winter;9(4):223-32. Alzheimer Dis Assoc Disord. 1995. PMID: 8749612 Clinical Trial.

8

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.

Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Schapiro MB, Rapoport SI, Soncrant TT. Asthana S, et al. Among authors: greig nh. Clin Pharmacol Ther. 1996 Sep;60(3):276-82. doi: 10.1016/S0009-9236(96)90054-5. Clin Pharmacol Ther. 1996. PMID: 8841150 Clinical Trial.

9

Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues.

Yu QS, Pei XF, Holloway HW, Greig NH, Brossi A. Yu QS, et al. Among authors: greig nh. J Med Chem. 1997 Aug 29;40(18):2895-901. doi: 10.1021/jm970210v. J Med Chem. 1997. PMID: 9288171

10

Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.

Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH. Lahiri DK, et al. Among authors: greig nh. Ann N Y Acad Sci. 1997 Sep 26;826:416-21. doi: 10.1111/j.1749-6632.1997.tb48495.x. Ann N Y Acad Sci. 1997. PMID: 9329715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

411 results

Search Page

Filters